Narrower Q2 Loss at Medivation


Medivation Inc. (MDVN) reported a second-quarter 2013 loss of 7 cents per share, narrower than the Zacks Consensus Estimate of a loss of 21 cents per share and the year-ago loss of 8 cents.

Revenues came in at $70.1 million, above the Zacks Consensus Estimate of $61 million and the year-ago revenues of $42.9 million.

The Quarter in Detail

Xtandi delivered net sales of $86.1 million (reported by Astellas (ALPMY)) in the second quarter, $10.7 million above the first quarter of 2013. U.S. sales were $82.4 million.

Xtandi is approved for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi is currently under regulatory review in several countries including Japan, Argentina, Australia, Brazil, South Africa and Switzerland.

Operating expenses increased 59.7% to $70.1 million. Research and development expenses increased 30.9% to $28.2 million. SG&A expenses increased 87.5% to $41.9 million.

2013 Outlook

Medivation still expects operating expenses (after adjusting cost-sharing payments) in the range of $285–$300 million. The company provided Xtandi U.S. net sales (reported by Astellas) guidance of $345-$365 million.

Medivation is working on expanding Xtandi’s label. Interim results from the phase III PREVAIL study on pre-chemo patients should be out later this year. The company also intends to start a phase III trial in patients with non-metastatic castration-resistant prostate cancer this year.

Xtandi is being evaluated in other studies as well, including a breast cancer study.

Our Take

We are encouraged by Xtandi’s performance. Xtandi could very well be a game-changer for Medivation. The prostate cancer market represents huge commercial potential and Xtandi is already off to a strong start. Launch in additional countries should drive sales further. Medivation has consistently presented impressive data on Xtandi. Expansion into the pre-chemo setting would be a major positive for Medivation.

Medivation is currently a Zacks Rank #3 (Hold) stock. At present, companies like Biogen Idec (BIIB) and Actelion Ltd. (ALIOF) look attractive with both being Zacks Rank #1 (Strong Buy) stocks.

Read the Full Research Report on ALIOF

Read the Full Research Report on MDVN

Read the Full Research Report on BIIB

Read the Full Research Report on ALPMY

Zacks Investment Research

More From
View Comments (0)